Business
DICOT: LIB-01 phase 2a trial fully funded after oversubscribed rights issue; Nasdaq listing approved
DICOT: LIB-01 phase 2a trial fully funded after oversubscribed rights issue; Nasdaq listing approved
About this update from Dicot Pharma Ab
No revenue reported as Dicot Pharma advances LIB-01, with phase 2a trial set for Q4 2024 and strong cash position after an oversubscribed rights issue. Nasdaq First North listing approved, and new R&D initiatives in metabolic diseases underway.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.